查詢結果分析
相關文獻
- 內皮素受體拮抗劑
- 內皮素受體拮抗劑:抗高血壓化合物及其與受體作用之研究
- 「內皮素受體拮抗劑:抗高血壓化合物及其與受體作用之研究」整合型研究計畫規劃報導
- 嚴重肺動脈高壓之病例用藥探討
- 肺動脈高壓治療的最新觀念
- Urinary Endothelin-1 in Patients with Renal Disease
- Serum Endothelin and Atrial Natriuretic Peptide in Cirrhotic Patients with Ascites and Hepatorenal Syndrome
- Changes of Endothelin-1 and Atrial Natriuretic Peptide during Dobutamine Stress Echocardiography
- 內皮素與腎臟
- 內皮素與疾病
頁籤選單縮合
題名 | 內皮素受體拮抗劑=Endothelin Receptor Antagonists |
---|---|
作者姓名(中文) | 李安榮; 林康媺; 黃文鑫; 陳秀和; | 書刊名 | 醫學研究 |
卷期 | 16:4 1996.01[民85.01] |
頁次 | 頁211-224 |
分類號 | 418.22 |
關鍵詞 | 內皮素; 內皮素受體拮抗劑; 非冴拮抗劑; Endothelin; Endothelin receptor antagonists; Non-peptidic antagonists; |
語文 | 中文(Chinese) |
中文摘要 | 內皮素(endothelin; ET)是由21個胺基酸組成的內生強力血管收縮肽,可能與人許多疾病有關,其分子內含兩個二硫化鍵(disulfide bond)。內皮素最初是由內皮細胞分離出,目前已知有三種內皮素:ET-1、ET-2及ET-3。ET-1會引起明顯的血管收縮等多種生理活性;ET-2並無特殊生理功能。內皮素受體亦分三種:ET(subscript A)、ET(subscript B)及ET(subscript C)。ET(subscript A)主要存在於血管平滑肌,對ET-1具有高選擇性。ET-1與ET(subscript A)結合後,引起強力血管收縮。ET(subscript B)與ET-1、ET-2、ET-3的親力相近,故不具選擇性。內皮素受體抗拮劑具仿內皮素與受體結合的主要立體結構點,使內皮素無法與受體結合,而產生拮抗作用。內皮素受體拮抗劑依化學結構,區分為兩大類:(一)肽化合物;(二)非肽分子。前者係含藥效基團的小分子肽;後者再分為蒽(anthraquinones), asterric acids, myricerone caffeoyl esters, N-嘧啶苯磺胺(N-pyrimidinylbenzenesulfonamides),N-異噁唑萘磺胺(N-isoxalylnaphthalenesulfonamides),二氫吡啶酐(dihydropyridine anhydrides),及氫茚羥酸(indanecarboxylic acids)等。其中屬N-嘧啶苯磺胺結構之ET(subscript A)強力競爭拮抗劑bosentan(11),是唯一進行臨床試驗的內皮素受體拮抗劑。內皮素受體拮抗劑對某些高血壓及急性腎衰竭等特定的動物疾病模式有效,但這類化合物在人體的療效,仍有待臨床評估。內皮素受體拮抗劑的快速發展,將使吾人進一步瞭解內皮素在病態生理學的角色,及其受體拮抗劑在臨床治療上的意義。 |
英文摘要 | Endothelin (ET), which is implicated in several human disease states including hypertension, congestive heart failure, pulmonary hypertension, ischemia, and cerebral vasospasm, is one of the most potent known vasoconstrictor peptides released from endothelial cells and has attracted tremendous interest as a possible target for therapeutic intervention. The ET family of 21-amino acid peptides (ET-1, ET-2, and ET-3) posses an unusual chemical structure containing two disulfide bonds. The ET receptors are differentiated by their relative affinities for the three isopeptides and designated ET(subscript A) (ET-1>ET-3), ET(subscript B) (ET-1=ET-3), and ETC (ET-3>ET-1), respectively. In this Review sone of the biological actions of the ET’s and their possible mechanisms of action were described. The final sections of this article discussed the recently reported ET receptor antagonists and their potential therapeutic applications. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。